TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement for completion of dispatch of Postal Ballot Notice.27-10-2023
27-10-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Copy of Postal Ballot Notice.26-10-2023
Hold Torrent Pharma; target of Rs 1940: ICICI Securities
ICICI Securities recommended hold rating on Torrent Pharma with a target price of Rs 1940 in its research report dated October 24, 2023.26-10-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of conference call with Analysts / Investors on Financial Results for the quarter and half year ended 30th September, 202326-10-2023
Buy Torrent Pharmaceuticals; target of Rs 2250: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2250 in its research report dated October 23, 2023.25-10-2023
Torrent Pharmaceuticals Ltd. Results Earnings Call for Q2FY24
Conference Call with Torrent Pharmaceuticals Ltd. Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.23-10-2023
Q2FY24 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals announced Q2FY24 results: 1. Revenues from India: In Q2FY24, Torrent Pharmaceuticals generated revenues of Rs 1,444 crore from its operations in India. This represents a growth of 18% compared to the same period last year. 2. Revenues from the United States: The company reported revenues of Rs 248 crore from its operations in the United States during Q2FY24. This reflects a decline of 15% compared to the corresponding quarter of the previous fiscal year. 3. Revenues from Germany: Torrent Pharmaceuticals generated revenues of Rs 266 crore from its operations in Germany in the Q2FY24. This indicates a growth of 21% compared to the same period last year. 4. Revenues from Brazil: The company reported revenues of Rs 252 crore from its operations in Brazil during Q2FY24.. This represents a substantial growth of 36% compared to the corresponding quarter of the previous fiscal year. 5. Revenues from Other Countries: Torrent Pharmaceuticals generated revenues of Rs 280 crore from its operations in other countries during the Q2FY24. This reflects a growth of 17% compared to the same period last year. 6. Other Revenues: The company reported revenues of Rs 170 crore from other sources during Q2FY24. 7.Overall, Torrent Pharmaceuticals reported total revenues of Rs 2,660 crore in Q2FY24, reflecting a growth of 16% compared to the same period last year. Result PDF23-10-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation23-10-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Financial Results For Quarter And Half Year Ended 30-Sep-23
Financial results for quarter and half year ended 30-sep-2323-10-2023
Torrent Pharmaceuticals Share Price Live blog for 23 Oct 2023
Torrent Pharmaceuticals stock price went down today, 23 Oct 2023, by -1.53 %. The stock closed at 1918.45 per share. The stock is currently trading at 1889.15 per share. Investors should monitor Torrent Pharmaceuticals stock price closely in the coming days and weeks to see how it reacts to the news.23-10-2023